The recurring translocation t(10;11)(p13;q14) which is found in acute myeloid leukemia (AML) and in acute lymphoblastic leukemia (ALL) results in the fusion of the putative transcription factor AF10 to CALM encoding a clathrin assembly protein. Previous studies using mainly fluorescence in situ hybridization (FISH) analysis have shown that the CALM/AF10 rearrangement is found in immature acute myeloid leukemia (AML) of subtype M0 and M1 and in T cell ALL. In this study we analyzed the CALM/AF10 and AF10/CALM fusion mRNAs in a series of three patients with AML, one patient with T-ALL and two patients with precusor T lymphoblastic lymphoma. In all six patients the breakpoint in CALM is at the 3Ј end of the coding region (nt1926/1927 or nt 2091/2092). Three breakpoints could be identified in AF10 (nt 588/589, nt 882/883 and nt 978/979). These data demonstrate that the CALM/AF10 fusions found in patients differ only slightly with respect to the portion of AF10 present and that there is no obvious difference between the fusions found in AML patients compared to those found in patients with lymphoid malignancies. Leukemia (2000) 14, 93-99.
Introduction
Recurring chromosomal translocations are frequently found associated with specific leukemia subtypes. 1 These translocations result either in the formation of fusion genes which act as oncogenes or in the transcriptional dysregulation of oncogenes. 2 The study of chromosomal translocations in leukemia has provided valuable insights into the molecular mechanism of malignant transformation in hematopoietic cells.
The rare but recurring translocation t(10;11)(p13;q14) has been observed in the leukemic cells of patients with AML as well as with ALL. [3] [4] [5] This translocation results in the fusion of CALM, a member of the ap-3-like family of clathrin assembly proteins, with the putative zinc finger transcription factor AF10 located at 10p13 and was originally cloned in the monocytic cell line U937. 6 In U937 the breakpoint in CALM is very close to the end of the 652 amino acid long open reading frame. The breakpoint in AF10 is close to the beginning of the open reading frame (after the first 80 of more than 1000 amino acids). Both fusion mRNAs can be identified in U937 but due to the asymmetric position of the breakpoints in the two genes the resulting fusion proteins are of very unequal size: the CALM/AF10 fusion protein would comprise almost the complete open reading frame of both CALM and AF10 whereas the AF10/CALM fusion protein would consist only of the first 80 amino acids of AF10 and the last four amino acids of CALM.
AF10 was first identified as the fusion partner of MLL in a t(10;11)(p13;q23) translocation. 7, 8 This translocation is often complex involving an inverted insertion of part of the long arm of chromosome 11 into the short arm of chromosome 10.
9,10 The MLL/AF10 fusion is almost exclusively found in patients with AML of FAB subtype M4 or M5. 7, 9 Molecular characterization of this fusion in a series of patients showed that only the MLL/AF10 fusion mRNA is present and that there are two breakpoint clusters in the AF10 gene: one immediately after the zinc finger region and the other just amino terminal to the leucine zipper. 7 We and others have previously shown by FISH analysis that the CALM and AF10 genes are rearranged in a certain subset of patients with a t(10;11). 11, 12 These patients had AML involving immature cells with FAB subtypes M0 and M1 as well as ALL. However, due to technical limitations we were unable to analyze the fusion mRNAs of CALM and AF10 in these patients. It was thus an unanswered question whether the different phenotypes observed in these patients would be due to variations in breakpoint locations in CALM and/or AF10 or whether the phenotypes would be influenced by other events. We therefore analyzed the fusion mRNAs in a series of six patients with t(10;11)(p13;q14) by RT-PCR including three patients in whom the CALM/AF10 rearrangement had previously been detected by FISH.
Materials and methods

Patient samples
The three AML patients (Nos 1-3) had been reported previously by us (patients 7, 8 and 9 in Ref. 12). These patients participated in the German AML Cooperative Group 86 and 92. 13 The ALL patient (4) and the two lymphoblastic lymphoma patients (5 and 6) were found to have a t(10;11) on routine cytogenetic analysis of malignant cells at the Kiel Institute of Human Genetics. All cases were reviewed and classified according to the French-American-British (FAB) criteria or the revised European-American classification by an independent reference hematopathologist. 14, 15 Immunophenotyping was performed according to the consensus protocol for flow cytometric immunophenotyping of hematopoietic malignancies. 12, 16 The clinical data of the patients were provided by the AMLCG and the NHL-BFM95 study centers. Bone marrow cells preserved in Carnoy's solution were obtained from patients 1 to 3; frozen bone marrow samples (patients 4 and 5) or lymph node samples (patient 6) were available from the other patients. Samples were taken at diagnosis except in case 5 where the sample was taken at relapse.
RT-PCR
For patients 1-3 total RNA was isolated from cells fixed in Carnoy's solution using the RNeasy kit (Qiagen, Hilden, Germany). For patients 4-6 total RNA was isolated using TriReagent (Sigma, Steinheim, Germany). RNA was reverse transcribed into cDNA using oligo-dT and random hexamer primers and MMLV-reverse transcriptase (Clontech, Heidelberg, Germany) or Superscript II (Gibco BRL, Karlsruhe, Germany). PCR was performed using standard buffer conditions (1.5 mM MgCl 2 , 50 mM KCl 2 , 10 mM TrisHCl pH 8.3) with 45 s denaturation at 94°C, 45 s annealing at 56°C and 1 min elongation at 72°C. cDNA quality was controlled by amplification of AF10 (primers: AN.T288 and AF10.949B) and CALM (NG.T45 and AN.B497). Primers are listed in Table 1 . For sequencing, PCR products were reamplified using primers with (CUA) 4 tails and cloned into pAMP10 (GibcoBRL). 17 Recombinant clones were isolated and sequenced using dyedeoxy terminators (ABI, Weiterstadt, Germany).
Results
Patient characteristics
Patients 1-3 have been reported previously. 12 Patient 4 was diagnosed with T-ALL. Immunophenotyping in patient 4 disclosed an immature T cell phenotype with expression of CD3 and CD10 and negativity of CD4, CD8 as well as the B cellassociated antigens CD19, CD20 and CD22. He achieved complete remission after a second induction therapy. The patient was still alive 5 months after initial diagnosis.
Patient 5 was initially diagnosed with malignant lymphoma (precursor T lymphoblastic lymphoma). She achieved complete remission with the NHL-BFM-95 study protocol but relapsed after 25 months. Another remission could not be achieved and she died 30 months after initial diagnosis. Immunophenotyping showed expression of the early T cell-specific antigen CD3 (cytoplasmic) and CD7 as well as some progenitor antigens (CD34, CD45). Again, the more mature T cellspecific antigens like CD4 and CD8 and the B cell-specific antigens CD20, CD22 and CD24 were negative. Interestingly, there was coexpression of the panmyeloid antigens CD13 and CD33.
Patient 6 presented with malignant lymphoma (precursor T lymphoblastic lymphoma). His lymphoblasts showed predominant expression of the T cell-associated antigens. No expression of B cell-specific (CD19, CD20) or myeloid anti- gens (CD13, CD33, and CD65s) was found. The patient was still alive after a 13 month follow-up. All six patients showed a very aggressive disease course. The AML patients 1, 2 and 3 survived for 1, 3 and 11 months, respectively. Patient 5 died in relapse 30 months after diagnosis. Patient 4 and 6 (T-ALL and precursor T lymphoblastic lymphoma) were still alive at 5 and 13 months after diagnosis (follow-up time). All patients except for patients 2 and 6 were between 16 and 22 years at diagnosis. Patient 2 was 47 years at diagnosis and patient 6 was only 5 years at diagnosis.
Patient characteristics, karyotype, immunophenotype and the breakpoints observed in the fusion mRNAs are summarized in Table 2 .
RT-PCR
RNA was successfully isolated from the cells stored in Carnoy's solution of the three AML patients that had been previously identified by FISH to have a CALM/AF10 rearrangement. 12 Amplification with a CALM forward (CALM1732T or NA.T501) and an AF10 reverse primer (AF10.651B or AF10.949B) yielded amplification products in all three AML patients (Nos 1-3).
Cloning and sequencing of the amplification products from these three patients revealed two breakpoints in CALM (nt1926/1927 and nt2091/2092) and two breakpoints in AF10 between nt588/589 (patient 3) or between nt882/883 (patients 1 and 2). Both CALM breakpoints were present in patient 1 and patient 3 which is most likely the result of alternative splicing between nt1927 and 2091 (55 amino acids). The reciprocal AF10/CALM fusion mRNAs were amplified from patients 1 and 3. The breakpoints observed in the AF10/CALM fusion mRNAs corresponded to the expected reciprocal rearrangements. In patient 1 the break in AF10 was between nt882/883 and in patient 3 between nt588/589. Only one breakpoint in CALM between CALM nt2091/2092 was observed in the AF10/CALM fusions of patients 1 and 3 ( Table 2 ).
The T-ALL case (patient 4) and the two malignant lymphoma cases (patients 5 and 6) were found to have a t(10;11)(p13;q14) translocation on routine cytogenetic examination. No FISH analysis was performed in these patients. RT-PCR using CALM forward and AF10 reverse primers revealed three types of CALM/AF10 fusions. In patient 4, the CALM/AF10 fusion joined CALM nt 2091 with AF10 nt 589 ( Figure 1) ; in patient 5, CALM nt 1926 joined with AF10 nt 883; in patient 6, CALM nt 2091 joined AF10 nt 979. A We were unable to amplify the reciprocal AF10/CALM fusion mRNA from any of the three patients with lymphoid neoplasias despite the fact that the mRNA was of good quality as shown by the amplification of the CALM/AF10 fusions and the wild-type AF10 mRNA (Figure 1 ). Even the design of new primers (AF10T238 and CALMB2182) that showed a much improved amplification of the AF10/CALM fusion in U937 as compared to the primers used previously (AN.T288, AF10.492T and AN.B497) and a nested PCR strategy did not result in amplification of the AF10/CALM fusion in patients 4-6.
Discussion
The t(10;11)(p13;q14) translocation originally cloned in the monocytic cell line U937 is interesting in several respects: (1) It results in the fusion of the putative transcription factor AF10 with CALM, a member of the clathrin assembly protein family. (2) The CALM/AF10 rearrangement is found in the leukemic cells of patients with acute myeloid as well as acute lymphoblastic leukemia or malignant lymphoma. (3) It was the first example that a fusion partner of MLL, ie AF10, could have another fusion partner.
After the initial characterization of the CALM/AF10 rearrangement in U937 it was not known how common this fusion event would be. Using interphase FISH we and others have demonstrated that CALM/AF10 rearrangements occur in both AML and ALL patient samples. However, these studies were not able to address the question whether there are differences at the molecular level in the CALM/AF10 rearrangements seen in these patients and whether such differences might correlate with the disease phenotype. The study presented here, as well as the study of Carlson et al 18 clearly demonstrates that there is limited variability in the breakpoint location in AF10 and a clustering of breakpoints at the 3Ј end of CALM. However, there seems to be no obvious correlation between the location of the breakpoint in AF10 and disease phenotype, especially when comparing patients with AML vs patients with ALL or lymphoma. These results are consistent with the observations from two other recent studies: Silliman et al 19 (one patient), Kumon et al 20 (five patients). All break- 18 patients 1 and 2 20 ). The breakpoints in CALM are restricted to the very 3Ј end of CALM coding region at nucleotides 1926, 1986 20 and 2091. We observed two alternatively spliced versions of the CALM/AF10 fusion mRNA (one breaking at CALM nt 1926 the other at CALM nt 2091) in two of our patients (1 and 3) . This alternative splicing has also been reported by Silliman and coworkers 19 and for patients 1 and 3 by Kumon and coworkers. 20 We only observed the nt 1926 break in patients 2 and 5, although we might have missed the alternatively spliced longer fusion mRNA with the break at nt 2091. Unfortunately, we were not able to amplify the AF10/CALM fusion mRNAs in these cases which would have helped to establish the true breakpoint in CALM. It is thus conceivable that all five patients have the genomic breakpoint in the same CALM intron which separates nt 2091 and 2092.
A greater variability in breakpoint position is seen when AF10 is fused to MLL in the t(10;11)(p13;q23). 7 This rearrangement is often associated with an inverted insertion of 11q into 10p. 9 There are two breakpoint clusters in AF10 in the MLL/AF10 fusion. The molecular analysis of a complex t(10;11) which results in the MLL/AF10 fusion showed that the reciprocal AF10/MLL is not present. 10 Although we tried several times using different conditions and primers we failed to amplify the reciprocal AF10/CALM fusion from patients 4, 5 and 6. We cannot Leukemia exclude that this inability to amplify the AF10/CALM fusion is due to technical problems. However, similar observations were made by Carlson et al. 18 Therefore, our results probably reflect the much lower abundance or possible absence of this fusion transcript in lymphoid neoplasias.
We have argued previously that the critical event responsible for malignant transformation is the CALM/AF10 fusion and not the reciprocal AF10/CALM fusion. 6 The apparent absence or extremely low abundance of the AF10/CALM fusion mRNA in a number of cases argues in favor of this hypothesis.
Several cases (patients 1 and 3, this study; patients 1, 2 and 5;
18 patient 1; 19 patient 2 20 ) had the t(10;11)(p13;q114) as their sole structural chromosomal abnormality (isochromosomes resulting from breaks in the heterochromatic or centromeric regions were not counted). This strongly indicates that the CALM/AF10 fusion could be the primary event leading to malignant transformation of the hematopoietic cells.
Little is known about the physiological function of AF10 or CALM. AF10 is a putative transcription factor. It is not known whether the zinc finger region which comprises a PHD zinc finger is involved in DNA binding or protein-protein interaction. 21 There is some indication that AF10 might play a role in maintaining cells in a differentiated state. 22 Thus one of the consequences of the CALM/AF10 fusion could be disruption of normal AF10 function. Supporting this hypothesis is the fact that by Northern analysis there is no normal AF10 transcript present in U937. 6 RT-PCR failed to amplify normal AF10 across the breakpoint in U937 (Bohlander, unpublished results). However, FISH using CEPH YAC 807b3 which contains AF10 did not show any apparent deletion on the normal chromosome 10.
Preliminary data using a GFP-CALM/AF10 protein expressed in NIH3T3 fibroblast suggest a cytoplasmic localization of this protein (data not shown). This mislocalization of the AF10 portion of CALM/AF10 would prevent AF10 from functioning in the nucleus. Alternatively, if AF10 acted as Leukemia a homodimer, a CALM/AF10 fusion could also exert a dominant-negative effect on AF10 function.
On the other hand, it has recently been shown that the clathrin heavy chain is the major protein interaction partner of CALM and that overexpression of CALM will inhibit receptormediated endocytosis. 23 Thus, one could imagine that disruption of normal CALM function by the CALM/AF10 fusion protein could significantly alter the dynamics of clathrinmediated growth factor receptor turn-over, which in turn could alter the sensitivity of the cells to external factors.
Although most of the leukemias studied here were clearly diagnosed as either myeloid or lymphoid, it is striking that both the myeloid and the lymphoid leukemias were classified as very immature. In one case (patient 1) it was only the cytochemistry staining that allowed unequivocal assignment to the myeloid lineage. It could thus be argued that the CALM/AF10 rearrangement is the hallmark of an early stem cell leukemia and that the phenotype observed (myeloid vs lymphoid) is either due to stochastic events (eg the microenvironment) or due to secondary genetic changes. Similar conclusions were drawn by Kobayashi et al. 11 However, sometimes a CALM/AF10 rearrangement is associated with a more differentiated myeloid leukemia of M5 subtype (U937; 6,24 patient 5 and 7;
11,20 patient 3 18 ). The prognosis for patients with a AML and a CALM/AF10 rearrangement is very poor. 12 The one lymphoma patient in this study with sufficient follow-up time died 30 months after initial diagnosis.
In conclusion, further dissection of the various aspects of malignant transformation initiated by the CALM/AF10 fusion will provide valuable insights into the mechanisms of leukemogenesis.
Note added in proof
While this manuscript was in the reviewing process a study by Narita et al 25 was published which also points to the importance of the CALM/AF10 fusion transcript in malignant hematological disease.
